About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance

By: ACN Newswire
HANGZHOU, CHINA, Jan 12, 2022 - (ACN Newswire) - On January 8, AIM Vaccine held a meeting at Shulan (Hangzhou) Hospital to report on the analysis results of the phase I clinical trial data of its mRNA COVID-19 vaccine (LVRNA009). Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration. Also, Dr. Shan Chao from Wuhan Institute of Virology, CAS announced the virus neutralizing antibody test at the meeting, "the GMT on day 56 of the adult low-dose group, the adult medium-dose group and the adult high-dose group was 576.6, 1591.2 and 845.7 respectively." Compared to the phase I clinical trial results of similar products, it demonstrated excellent safety and immunogenicity. At present, the phase I clinical trials of all 3 China's mRNA vaccines are carried out at the Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, among which the first mRNA vaccine is already under phase III clinical trial overseas.

At the meeting, top-notch experts acclaimed the phase I results of the mRNA COVID-19 vaccine (LVRNA009) of AIM Vaccine. Based on the current situation of pandemic prevention and control, experts expressed that drugs will not bring an end to the pandemic; vaccine remains the most effective means of prevention and control, and will continue to be applied on a large scale; thus, the sequential immunization with COVID-19 vaccine in China is of great significance. Renowned public health expert and epidemiologist Zeng Guang believed that novel coronavirus may be continuously weakening but cannot be eliminated, and it may coexist with the mankind over the long term; therefore, China must implement sequential immunization to establish a solid and most effective barrier of colony immunity. Zeng Guang expressed the importance of vaccination in plain language: "With vaccine, there is nothing to be afraid of!" Professor Wang Yu - distinguished visiting professor from Vanke School of Public Health, Tsinghua University and former director of Chinese Center for Disease Control and Prevention - elaborated on his opinion with the examples of H7N9 and poliomyelitis. According to him, antivirus drug is not the ultimate solution to the spread and infection of virus, and COVID-19 vaccine will continue to be used on a large scale. Professor Wang explained how mRNA technology can be applied in vaccines, and pointed out that our understanding of the biological behaviors of novel coronavirus is far from enough due to the suddenness of its outbreak, which requires the efforts of R&D enterprises and scientists and endless researches on new vaccine technologies. Distinguished professor of Fudan University and researcher of Institutes of Biomedical Sciences Xu Jianqing set forth the challenges in COVID-19 prevention and control and the latest progress of vaccines. At present, the proportion of asymptomatic infection remains high, and it is an extremely challenging task to achieve colony immunity through infection or a single vaccine. Xu said mRNA vaccine has obvious advantages as a booster short in view of its antibody durability and response to variants.

Prof. Peng Yucai, lead scientist of AIM vaccine, expounded on the features of its mRNA COVID-19 vaccine at the meeting, with a comprehensive introduction made to its advantages in terms of gene sequence design, mRNA delivery method, vaccine stability and product quality control. Prof. Peng said, the mRNA COVID-19 vaccine (LVRNA009) originated from the R&D base of LIVERNA, which has begun its R&D of mRNA vaccine since 2017 as the first in China. In addition to a strong team and its mRNA R&D technology, LIVERNA also has its own pilot-scale production workshop for producing phase I and phase I clinical samples, which guarantees the quality control of its mRNA products. He commented, "This is rare." In addition, the internationally most advanced and most widely applied LNP delivery technology is adopted for this mRNA COVID-19 vaccine, its advantages including higher mRNA encapsulation and delivery efficiency than all previous technologies, good and controllable particle homogeneity, relatively simple production process, and easily realizable scale-up. "Now, our confidence in its R&D is boosted by factors on every aspect."

Prof. Qin Xiaofeng of Systems Research Center of Institute of Basic Medical Sciences (Chinese Academy of Medical Sciences & Peking Union Medical College) and Suzhou Institute of Systems Medicine felt heartened by the phase I clinical trial data of AIM mRNA vaccine. He expressed: "With few adverse reactions and high neutralizing antibody titer, this product has great prospects."

Besides clinical research, the industrialization of mRNA COVID-19 vaccine is another hot topic at the meeting. Dr. Xiong Changyun, who is charge of mRNA industrialization at AIM Vaccine, introduced the future path of industrialization of its mRNA vaccines. With modular workshops for mRNA vaccine production under planning in Ningbo, Shanghai and/or Beijing, AIM Vaccine has confidence in satisfying the market demands with its production capacity.





Copyright 2022 ACN Newswire . All rights reserved.

More News

View More
3 Heavily Shorted Stocks That Could Pop on Rate Cuts
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers ETSY SMR SOUN
Broadcom Gets Second $420 Target as CPO Win Boosts Outlook
Via MarketBeat
Tickers AVGO META
PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can
Via MarketBeat
Tickers PEP
Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been
Via MarketBeat
Tickers DKNG
Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom
Via MarketBeat
Tickers BUD STZ
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.